In a study by Dong et al., loss‐of‐function SETD2 mutations in acute leukemia showed downregulation of genes involved in S and G2/M cell cycle progression, which conferred resistance to standard cytarabine‐based chemotherapy drugs.32 This evidence concerns the gene SETD2 and acute leukemia.